US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Boundless Bio, Inc.

1.16

+0.07006.42%

Post-market: 1.160.00000.00%16:00 EST

Volume:285.02K

Turnover:327.68K

Market Cap:25.97M

PE:-0.42

High:1.19

Open:1.14

Low:1.13

Close:1.09

52wk High:2.48

52wk Low:0.9612

Shares:22.39M

Float Shares:16.46M

Volume Ratio:0.89

T/O Rate:1.73%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.7644

EPS(LYR):-3.8485

ROE:-44.88%

ROA:-24.66%

PB:0.24

PE(LYR):-0.30

Loading ...

Overview Company News Filings

Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Boundless ceases enrollment of Phase 1/2 Potentiate trial of BBI-355, BBI-825

Boundless Bio Unveils ecDNA-Directed Cancer Therapy Strategy in New Presentation

Boundless Bio Inc: Bbi-940 Ind Accepted; Initiation of First-in-Human Clinical Trial on Track for First Half of 2026

THOMSON REUTERS

Boundless Bio Inc: Portfolio Prioritization, Including Discontinuation of Potentiate Trial, Extends Operating Runway Into H2 2028

THOMSON REUTERS

FDA Accepts IND Application for Boundless Bio's BBI-940

Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway

NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM

Boundless Bio Terminates Early-Stage BBI-825 Cancer Trial: What Investors Should Know

21shares launches BOLD ETP combining bitcoin and gold in a single regulated product

Gold’s bull run is set to continue in 2026, and crypto’s weakness could boost silver higher – ByteTree’s Charlie Morris

Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference

Boundless Bio Unveils New Therapies Targeting ecDNA-Driven Cancer

Boundless Bio Q3 EPS $(0.62) Misses $(0.53) Estimate

Boundless Bio Inc: Qtrly EPS $-0.62

THOMSON REUTERS

Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights

Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

ESQUIRE VIETNAM RELAUNCHES WITH A BOLD VISION, CELEBRATING THE AGE OF EXCELLENCE

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BOLD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BOLD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BOLD\",,,,,undefined,":{"symbol":"BOLD","market":"US","secType":"STK","nameCN":"Boundless Bio, Inc.","latestPrice":1.16,"timestamp":1770411600000,"preClose":1.09,"halted":0,"volume":285016,"hourTrading":{"tag":"盘后","latestPrice":1.16,"preClose":1.16,"latestTime":"16:00 EST","volume":259,"amount":300.44,"timestamp":1770411632219,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.06422018348623838,"floatShares":16462050,"shares":22385611,"eps":-2.764393,"marketStatus":"Market Closed","change":0.07,"latestTime":"02-06 16:00:00 EST","open":1.14,"high":1.19,"low":1.125,"amount":327678.6417,"amplitude":0.059633,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.764393,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1711598400000,"exchange":"NASDAQ","adjPreClose":1.09,"preHourTrading":{"tag":"盘前","latestPrice":1.13,"preClose":1.09,"latestTime":"09:29 EST","volume":4734,"amount":5264.820106200001,"timestamp":1770388199114,"change":0.04,"changeRate":0.036697,"amplitude":0.036697},"postHourTrading":{"tag":"盘后","latestPrice":1.16,"preClose":1.16,"latestTime":"16:00 EST","volume":259,"amount":300.44,"timestamp":1770411632219,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8897429938802568},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BOLD\",,,,,undefined,":{"symbol":"BOLD","floatShares":16462050,"roa":"-24.66%","roe":"-44.88%","lyrEps":-3.848504,"volumeRatio":0.8897429938802568,"shares":22385611,"dividePrice":0,"high":1.19,"amplitude":0.059633,"preClose":1.09,"low":1.125,"week52Low":0.9612,"pbRate":"0.24","week52High":2.48,"institutionHeld":0,"latestPrice":1.16,"eps":-2.764393,"divideRate":0,"volume":285016,"delay":0,"ttmEps":-2.764393,"open":1.14,"prevYearClose":1.2,"prevWeekClose":1.16,"prevMonthClose":1.16,"prevQuarterClose":1.2,"fiveDayClose":1.16,"twentyDayClose":1.31,"sixtyDayClose":1.21},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BOLD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-05","symbol":"BOLD","fiscalQuarterEnding":"2025/09","expectedEps":-0.53,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"pre","actualEps":-0.62},{"market":"US","date":"2025-08-05","symbol":"BOLD","fiscalQuarterEnding":"2025/06","expectedEps":-0.75,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754366400000,"reportTimeType":"pre","actualEps":-0.7}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BOLD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BOLD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":2,"updateTime":1748840400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BOLD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BOLD","date":"2026-02-06","current":-0.419622,"percent":0.907725,"low":-7.197589,"twenty":-1.422549,"median":-0.629965,"eighty":-0.410208,"high":-0.344156,"avg":-1.232174,"sd":1.349167,"marketCap":24398701},"quantilePoints":[{"date":"2024-03-28","current":-7.197589,"twenty":-7.197589,"median":-7.197589,"eighty":-7.197589,"marketCap":355805632},{"date":"2024-04-05","current":-5.848041,"twenty":-6.410353,"median":-6.108954,"eighty":-6.050474,"marketCap":289092076},{"date":"2024-04-12","current":-5.231748,"twenty":-6.126948,"median":-5.947008,"eighty":-5.398192,"marketCap":258626218},{"date":"2024-04-19","current":-5.083297,"twenty":-6.09096,"median":-5.501658,"eighty":-5.078799,"marketCap":251287727},{"date":"2024-04-26","current":-5.429681,"twenty":-6.050474,"median":-5.339712,"eighty":-4.853874,"marketCap":268410873},{"date":"2024-05-03","current":-4.071136,"twenty":-5.947008,"median":-5.193511,"eighty":-4.750409,"marketCap":201252560},{"date":"2024-05-10","current":-4.093629,"twenty":-5.848041,"median":-5.078799,"eighty":-4.498493,"marketCap":202364453},{"date":"2024-05-17","current":-4.480499,"twenty":-5.605123,"median":-4.907856,"eighty":-4.413022,"marketCap":221489005},{"date":"2024-05-24","current":-4.735651,"twenty":-5.429681,"median":-4.853874,"eighty":-4.413022,"marketCap":234102149},{"date":"2024-05-31","current":-3.818758,"twenty":-5.40449,"median":-4.780666,"eighty":-4.267271,"marketCap":202947870},{"date":"2024-06-07","current":-4.028119,"twenty":-5.351408,"median":-4.637315,"eighty":-4.062533,"marketCap":214074398},{"date":"2024-06-14","current":-2.746826,"twenty":-5.256939,"median":-4.498493,"eighty":-3.894843,"marketCap":145980047},{"date":"2024-06-21","current":-1.997311,"twenty":-5.233547,"median":-4.480499,"eighty":-3.836344,"marketCap":106147077},{"date":"2024-06-28","current":-1.62046,"twenty":-5.185863,"median":-4.433265,"eighty":-3.622795,"marketCap":86119326},{"date":"2024-07-05","current":-1.737702,"twenty":-5.126483,"median":-4.318554,"eighty":-2.862394,"marketCap":92350182},{"date":"2024-07-12","current":-1.708392,"twenty":-5.081498,"median":-4.206091,"eighty":-2.280368,"marketCap":90792468},{"date":"2024-07-19","current":-1.490655,"twenty":-5.078799,"median":-4.082382,"eighty":-1.861645,"marketCap":79220879},{"date":"2024-07-26","current":-1.553464,"twenty":-5.032015,"median":-4.019745,"eighty":-1.783761,"marketCap":82558837},{"date":"2024-08-02","current":-1.33154,"twenty":-4.961394,"median":-3.883354,"eighty":-1.756126,"marketCap":70764718},{"date":"2024-08-09","current":-1.285481,"twenty":-4.955327,"median":-3.848068,"eighty":-1.688293,"marketCap":68316881},{"date":"2024-08-16","current":-1.276053,"twenty":-4.909884,"median":-3.776885,"eighty":-1.61376,"marketCap":73657615},{"date":"2024-08-23","current":-1.441824,"twenty":-4.830482,"median":-3.580085,"eighty":-1.533365,"marketCap":83226429},{"date":"2024-08-30","current":-1.395563,"twenty":-4.789503,"median":-2.891285,"eighty":-1.49233,"marketCap":80556062},{"date":"2024-09-06","current":-1.206661,"twenty":-4.774615,"median":-2.543744,"eighty":-1.430642,"marketCap":69652065},{"date":"2024-09-13","current":-1.383997,"twenty":-4.747457,"median":-2.265294,"eighty":-1.38631,"marketCap":79888471},{"date":"2024-09-20","current":-1.696264,"twenty":-4.696317,"median":-1.886349,"eighty":-1.383997,"marketCap":97913446},{"date":"2024-09-27","current":-1.306894,"twenty":-4.531782,"median":-1.821447,"eighty":-1.360095,"marketCap":75437859},{"date":"2024-10-04","current":-1.225936,"twenty":-4.502092,"median":-1.785855,"eighty":-1.334651,"marketCap":70764718},{"date":"2024-10-11","current":-1.164254,"twenty":-4.498493,"median":-1.762826,"eighty":-1.315376,"marketCap":67204229},{"date":"2024-10-18","current":-1.175819,"twenty":-4.494894,"median":-1.752358,"eighty":-1.306512,"marketCap":67871820},{"date":"2024-10-25","current":-1.125702,"twenty":-4.475101,"median":-1.708392,"eighty":-1.277939,"marketCap":64978923},{"date":"2024-11-01","current":-1.148833,"twenty":-4.453508,"median":-1.660521,"eighty":-1.239044,"marketCap":66314106},{"date":"2024-11-08","current":-1.278189,"twenty":-4.445411,"median":-1.62046,"eighty":-1.227478,"marketCap":78044967},{"date":"2024-11-15","current":-1.099243,"twenty":-4.400426,"median":-1.603711,"eighty":-1.225936,"marketCap":67118671},{"date":"2024-11-22","current":-0.858213,"twenty":-4.337447,"median":-1.553464,"eighty":-1.206661,"marketCap":52401620},{"date":"2024-11-29","current":-0.996988,"twenty":-4.287064,"median":-1.515072,"eighty":-1.18353,"marketCap":60875074},{"date":"2024-12-06","current":-1.033507,"twenty":-4.282566,"median":-1.492749,"eighty":-1.171964,"marketCap":63104930},{"date":"2024-12-13","current":-0.898385,"twenty":-4.206091,"median":-1.45339,"eighty":-1.168109,"marketCap":54854462},{"date":"2024-12-20","current":-0.94586,"twenty":-4.174602,"median":-1.427126,"eighty":-1.164254,"marketCap":57753275},{"date":"2024-12-27","current":-0.931252,"twenty":-4.109824,"median":-1.4052,"eighty":-1.151917,"marketCap":56861333},{"date":"2025-01-03","current":-0.978728,"twenty":-4.080133,"median":-1.38978,"eighty":-1.137518,"marketCap":59760146},{"date":"2025-01-10","current":-0.883777,"twenty":-4.053929,"median":-1.382892,"eighty":-1.125702,"marketCap":53962520},{"date":"2025-01-17","current":-0.923948,"twenty":-4.024769,"median":-1.357011,"eighty":-1.113366,"marketCap":56415361},{"date":"2025-01-24","current":-0.880125,"twenty":-4.002159,"median":-1.351229,"eighty":-1.080253,"marketCap":53739534},{"date":"2025-01-31","current":-0.836301,"twenty":-3.925951,"median":-1.335808,"eighty":-1.010135,"marketCap":51063706},{"date":"2025-02-07","current":-0.810737,"twenty":-3.894843,"median":-1.330025,"eighty":-0.986762,"marketCap":49502807},{"date":"2025-02-14","current":-0.818041,"twenty":-3.863491,"median":-1.312677,"eighty":-0.98238,"marketCap":49948778},{"date":"2025-02-21","current":-0.715786,"twenty":-3.86063,"median":-1.307149,"eighty":-0.967772,"marketCap":43705181},{"date":"2025-02-28","current":-0.70483,"twenty":-3.848068,"median":-1.306417,"eighty":-0.938556,"marketCap":43036224},{"date":"2025-03-07","current":-0.617183,"twenty":-3.818758,"median":-1.293401,"eighty":-0.934904,"marketCap":37684569},{"date":"2025-03-14","current":-0.613531,"twenty":-3.802009,"median":-1.278189,"eighty":-0.9276,"marketCap":37461584},{"date":"2025-03-21","current":-0.642747,"twenty":-3.751762,"median":-1.256474,"eighty":-0.920296,"marketCap":39245469},{"date":"2025-03-28","current":-0.511724,"twenty":-3.651268,"median":-1.237502,"eighty":-0.912992,"marketCap":33447843},{"date":"2025-04-04","current":-0.443494,"twenty":-3.580085,"median":-1.233647,"eighty":-0.891081,"marketCap":28988130},{"date":"2025-04-11","current":-0.416203,"twenty":-3.232545,"median":-1.225936,"eighty":-0.861865,"marketCap":27204245},{"date":"2025-04-17","current":-0.484432,"twenty":-3.075105,"median":-1.212454,"eighty":-0.839223,"marketCap":31663958},{"date":"2025-04-25","current":-0.50149,"twenty":-2.80461,"median":-1.206661,"eighty":-0.818041,"marketCap":32778886},{"date":"2025-05-02","current":-0.547545,"twenty":-2.616184,"median":-1.18353,"eighty":-0.802703,"marketCap":35789192},{"date":"2025-05-09","current":-0.490678,"twenty":-2.519877,"median":-1.175819,"eighty":-0.736237,"marketCap":32233147},{"date":"2025-05-16","current":-0.562236,"twenty":-2.343176,"median":-1.171964,"eighty":-0.7041,"marketCap":36933814},{"date":"2025-05-23","current":-0.531568,"twenty":-2.272831,"median":-1.168109,"eighty":-0.640556,"marketCap":34919242},{"date":"2025-05-30","current":-0.398676,"twenty":-2.104504,"median":-1.164254,"eighty":-0.625217,"marketCap":26189432},{"date":"2025-06-06","current":-0.398676,"twenty":-1.939527,"median":-1.156544,"eighty":-0.615722,"marketCap":26189432},{"date":"2025-06-13","current":-0.371416,"twenty":-1.883418,"median":-1.150761,"eighty":-0.59381,"marketCap":24398701},{"date":"2025-06-20","current":-0.354379,"twenty":-1.864994,"median":-1.144978,"eighty":-0.584315,"marketCap":23279495},{"date":"2025-06-27","current":-0.364601,"twenty":-1.841546,"median":-1.129558,"eighty":-0.573359,"marketCap":23951019},{"date":"2025-07-03","current":-0.364601,"twenty":-1.81726,"median":-1.125702,"eighty":-0.562917,"marketCap":23951019},{"date":"2025-07-11","current":-0.402084,"twenty":-1.799673,"median":-1.119919,"eighty":-0.547886,"marketCap":26413273},{"date":"2025-07-18","current":-0.402084,"twenty":-1.792136,"median":-1.099243,"eighty":-0.532375,"marketCap":26413273},{"date":"2025-07-25","current":-0.425936,"twenty":-1.772875,"median":-1.068201,"eighty":-0.524876,"marketCap":27980162},{"date":"2025-08-01","current":-0.403787,"twenty":-1.762826,"median":-1.033507,"eighty":-0.512406,"marketCap":26525194},{"date":"2025-08-08","current":-0.396302,"twenty":-1.761988,"median":-0.996988,"eighty":-0.507716,"marketCap":25517908},{"date":"2025-08-15","current":-0.406731,"twenty":-1.757801,"median":-0.986032,"eighty":-0.494667,"marketCap":26189432},{"date":"2025-08-22","current":-0.396302,"twenty":-1.753614,"median":-0.98238,"eighty":-0.472151,"marketCap":25517908},{"date":"2025-08-29","current":-0.396302,"twenty":-1.747752,"median":-0.978728,"eighty":-0.443077,"marketCap":25517908},{"date":"2025-09-05","current":-0.392826,"twenty":-1.737702,"median":-0.967772,"eighty":-0.423026,"marketCap":25294066},{"date":"2025-09-12","current":-0.403255,"twenty":-1.708392,"median":-0.944034,"eighty":-0.416203,"marketCap":25965590},{"date":"2025-09-19","current":-0.396302,"twenty":-1.696264,"median":-0.938556,"eighty":-0.40938,"marketCap":25517908},{"date":"2025-09-26","current":-0.392826,"twenty":-1.674894,"median":-0.934904,"eighty":-0.406731,"marketCap":25294066},{"date":"2025-10-03","current":-0.420637,"twenty":-1.646147,"median":-0.9276,"eighty":-0.406731,"marketCap":27084797},{"date":"2025-10-10","current":-0.444971,"twenty":-1.624647,"median":-0.925774,"eighty":-0.406731,"marketCap":28651686},{"date":"2025-10-17","current":-0.490163,"twenty":-1.62046,"median":-0.920296,"eighty":-0.408899,"marketCap":31561623},{"date":"2025-10-24","current":-0.490163,"twenty":-1.616272,"median":-0.914818,"eighty":-0.40938,"marketCap":31561623},{"date":"2025-10-31","current":-0.479734,"twenty":-1.612085,"median":-0.912992,"eighty":-0.40938,"marketCap":30890099},{"date":"2025-11-07","current":-0.456671,"twenty":-1.595336,"median":-0.898385,"eighty":-0.410208,"marketCap":28204003},{"date":"2025-11-14","current":-0.434925,"twenty":-1.566026,"median":-0.891081,"eighty":-0.410208,"marketCap":26860956},{"date":"2025-11-21","current":-0.402305,"twenty":-1.553464,"median":-0.870995,"eighty":-0.410208,"marketCap":24846384},{"date":"2025-11-28","current":-0.424052,"twenty":-1.526666,"median":-0.858213,"eighty":-0.409519,"marketCap":26189432},{"date":"2025-12-05","current":-0.398681,"twenty":-1.516051,"median":-0.836301,"eighty":-0.408465,"marketCap":24622543},{"date":"2025-12-12","current":-0.416803,"twenty":-1.508938,"median":-0.819867,"eighty":-0.409284,"marketCap":25741749},{"date":"2025-12-19","current":-0.460295,"twenty":-1.497355,"median":-0.814389,"eighty":-0.40938,"marketCap":28427845},{"date":"2025-12-26","current":-0.438549,"twenty":-1.49233,"median":-0.803433,"eighty":-0.409484,"marketCap":27084797},{"date":"2026-01-02","current":-0.434925,"twenty":-1.481917,"median":-0.796129,"eighty":-0.409816,"marketCap":26860956},{"date":"2026-01-09","current":-0.474793,"twenty":-1.462642,"median":-0.734046,"eighty":-0.410208,"marketCap":29323210},{"date":"2026-01-16","current":-0.453047,"twenty":-1.448764,"median":-0.70483,"eighty":-0.411047,"marketCap":27980162},{"date":"2026-01-23","current":-0.460295,"twenty":-1.439029,"median":-0.701178,"eighty":-0.412481,"marketCap":28427845},{"date":"2026-01-30","current":-0.427676,"twenty":-1.427558,"median":-0.657354,"eighty":-0.413179,"marketCap":26413273},{"date":"2026-02-06","current":-0.395057,"twenty":-1.422549,"median":-0.629965,"eighty":-0.410208,"marketCap":24398701}],"updateTime":1770460324106},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BOLD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609372831","title":"Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2609372831","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609372831?lang=en_us&edition=fundamental","pubTime":"2026-02-05 20:00","pubTimestamp":1770292800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Feb.  05, 2026  (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/05/3232819/0/en/Boundless-Bio-to-Participate-in-the-Guggenheim-Emerging-Outlook-Biotech-Summit-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMF","BK4211","BOLD","BK4585","BK4139","BK4588","LABU"],"gpt_icon":0},{"id":"2604718190","title":"Boundless ceases enrollment of Phase 1/2 Potentiate trial of BBI-355, BBI-825","url":"https://stock-news.laohu8.com/highlight/detail?id=2604718190","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604718190?lang=en_us&edition=fundamental","pubTime":"2026-01-20 20:15","pubTimestamp":1768911345,"startTime":"0","endTime":"0","summary":"Following a strategic portfolio review, Boundless Bio (BOLD) has elected to cease enrollment of the Phase 1/2 Potentiate trial evaluating the combi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/boundless-ceases-enrollment-of-phase-1-2-potentiate-trial-of-bbi-355-bbi-825-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/boundless-ceases-enrollment-of-phase-1-2-potentiate-trial-of-bbi-355-bbi-825-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BOLD"],"gpt_icon":0},{"id":"2604190194","title":"Boundless Bio Unveils ecDNA-Directed Cancer Therapy Strategy in New Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2604190194","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604190194?lang=en_us&edition=fundamental","pubTime":"2026-01-20 20:09","pubTimestamp":1768910989,"startTime":"0","endTime":"0","summary":"Boundless Bio Inc. has released a corporate presentation detailing its latest developments in cancer treatment targeting oncogene amplified cancers, which represent a significant unmet medical need with approximately 1.3 million new patients annually in major markets. The company highlights its focus on therapies directed at extrachromosomal DNA , a cancer-specific circular DNA implicated in oncogene amplification. Boundless Bio's drug discovery platform, Spyglass, is used to identify synthetic lethal targets in these cancers. The company’s pipeline includes BBI-940, an oral Kinesin degrader with an accepted IND and a clinical trial set to begin in the first half of 2026. In addition, four other ecDNA-selective targets are under development, with one at the hit-to-lead stage. Boundless Bio reports a cash runway expected to last into the second half of 2028, supporting continued research and development activities. You can access the full presentation through the link below.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL38nKtC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BOLD"],"gpt_icon":0},{"id":"2604190609","title":"Boundless Bio Inc: Bbi-940 Ind Accepted; Initiation of First-in-Human Clinical Trial on Track for First Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2604190609","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604190609?lang=en_us&edition=fundamental","pubTime":"2026-01-20 20:05","pubTimestamp":1768910704,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nFWN3YL0FC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BOLD"],"gpt_icon":0},{"id":"2604190606","title":"Boundless Bio Inc: Portfolio Prioritization, Including Discontinuation of Potentiate Trial, Extends Operating Runway Into H2 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2604190606","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604190606?lang=en_us&edition=fundamental","pubTime":"2026-01-20 20:05","pubTimestamp":1768910704,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nFWN3YL0FC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BOLD"],"gpt_icon":0},{"id":"2604919707","title":"FDA Accepts IND Application for Boundless Bio's BBI-940","url":"https://stock-news.laohu8.com/highlight/detail?id=2604919707","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604919707?lang=en_us&edition=fundamental","pubTime":"2026-01-20 20:00","pubTimestamp":1768910424,"startTime":"0","endTime":"0","summary":"Boundless Bio Inc. announced that the U.S. Food and Drug Administration  has accepted its Investigational New Drug  application for its novel Kinesin oral degrader program, BBI-940. This regulatory acceptance enables Boundless Bio to proceed with the initiation of a first-in-human clinical trial, which is on track to begin in the first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boundless Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on January 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL3fH6SH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","SG9999014013.SGD","BOLD","BK4139","LU0314104364.USD","LU2210150020.SGD","BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","SG9999014021.USD","SG9999014039.USD","NDAQ","BK4588","SG9999014005.SGD","IE00B64PRP62.GBP","BK4585","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2604619056","title":"Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway","url":"https://stock-news.laohu8.com/highlight/detail?id=2604619056","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604619056?lang=en_us&edition=fundamental","pubTime":"2026-01-20 20:00","pubTimestamp":1768910400,"startTime":"0","endTime":"0","summary":"BBI-940 IND accepted; initiation of first-in-human clinical trial on trackfor the first half of 2026 Portfolio prioritization, including discontinuation of POTENTIATE trial, extends operating runway i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/20/3221540/0/en/Boundless-Bio-Advances-Novel-Kinesin-Degrader-Program-BBI-940-and-Extends-Cash-Runway.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","BK4139","BOLD"],"gpt_icon":0},{"id":"2604974881","title":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 06:55 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2604974881","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604974881?lang=en_us&edition=fundamental","pubTime":"2026-01-20 19:55","pubTimestamp":1768910100,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 06:55 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nAQN2LIB60:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BOLD"],"gpt_icon":0},{"id":"2604478990","title":"Boundless Bio Terminates Early-Stage BBI-825 Cancer Trial: What Investors Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2604478990","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604478990?lang=en_us&edition=fundamental","pubTime":"2026-01-17 00:31","pubTimestamp":1768581094,"startTime":"0","endTime":"0","summary":"Boundless Bio Inc. ($BOLD) announced an update on their ongoing clinical study. Study Overview The study, formally titled “An Open-Label, Multicent...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/boundless-bio-terminates-early-stage-bbi-825-cancer-trial-what-investors-should-know?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/boundless-bio-terminates-early-stage-bbi-825-cancer-trial-what-investors-should-know?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4211","SSI","ISBC","BOLD"],"gpt_icon":0},{"id":"2603504366","title":"21shares launches BOLD ETP combining bitcoin and gold in a single regulated product","url":"https://stock-news.laohu8.com/highlight/detail?id=2603504366","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603504366?lang=en_us&edition=fundamental","pubTime":"2026-01-13 17:00","pubTimestamp":1768294800,"startTime":"0","endTime":"0","summary":"Approved by Archax 12/01/2026 Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Ta","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/13/3217495/0/en/21shares-launches-BOLD-ETP-combining-bitcoin-and-gold-in-a-single-regulated-product.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03439","09439","BK4594","ETH","BOLD","09042","IBIT","LSE","BK4585","03042","BTC","FSCS","FCA","BK4601","83042","09008","03008","BK4139","BK4588","BK1611","BK4179"],"gpt_icon":0},{"id":"2593448530","title":"Gold’s bull run is set to continue in 2026, and crypto’s weakness could boost silver higher – ByteTree’s Charlie Morris","url":"https://stock-news.laohu8.com/highlight/detail?id=2593448530","media":"Kitco","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593448530?lang=en_us&edition=fundamental","pubTime":"2025-12-23 20:01","pubTimestamp":1766491260,"startTime":"0","endTime":"0","summary":"(Kitco News) – While Bitcoin, AI and the tech sector are likely to take a step back in 2026, gold’s bull run still has legs – and crypto’s weakness could add to silver’s strength, according to Charlie","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"kitco_highlight","url":"https://www.kitco.com/news/article/2025-12-23/golds-bull-run-set-continue-2026-and-cryptos-weakness-could-boost-silver","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.kitco.com/news/article/2025-12-23/golds-bull-run-set-continue-2026-and-cryptos-weakness-could-boost-silver","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"kitco_highlight","symbols":["BK4601","BOLD","BK4139","BTC.USD.CC","BK4594","BK1611","BK4588","BTC","83042","BK4585"],"gpt_icon":0},{"id":"2585461626","title":"Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2585461626","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585461626?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:00","pubTimestamp":1763985600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Nov.  24, 2025  (GLOBE NEWSWIRE) -- Boundless Bio, (Nasdaq: BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/24/3193371/0/en/Boundless-Bio-to-Participate-in-the-Piper-Sandler-37th-Annual-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNR","BK4585","LABU","LU2244417387.USD","LU0187121727.USD","LU0347712357.USD","BK4137","LU1721428933.USD","LU0077335932.USD","LU2413666699.HKD","HCSG","BK4139","BK4019","LU0128526141.USD","XLV","XBI","BOLD","LU0029874061.USD","BK4588","BK4581","LU2413666426.HKD"],"gpt_icon":0},{"id":"2582801089","title":"Boundless Bio Unveils New Therapies Targeting ecDNA-Driven Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2582801089","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582801089?lang=en_us&edition=fundamental","pubTime":"2025-11-11 02:51","pubTimestamp":1762800661,"startTime":"0","endTime":"0","summary":"Boundless Bio Inc. has released a corporate presentation detailing its latest advancements in cancer treatment through ecDNA-directed therapies . The company highlights the significant unmet medical need for therapies targeting oncogene amplified cancers, which are generally unresponsive to existing targeted and immunotherapies. Boundless Bio's approach leverages extrachromosomal DNA , identified as a key driver of oncogene amplification in cancer. The presentation outlines the company's clinical-stage candidates, including BBI-355, an oral CHK1 inhibitor, and BBI-825, an oral RNR inhibitor, both being evaluated in the POTENTIATE clinical trial. Additionally, BBI-940, an oral Kinesin degrader, is expected to begin clinical trials in the first half of 2026. According to the company, approximately 25% of cancer patients have amplified oncogenes, with about half of high-copy number amplifications occurring on ecDNA. There are currently no approved therapies for these cancers, except for H","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL7ppXqg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BOLD"],"gpt_icon":0},{"id":"2581721499","title":"Boundless Bio Q3 EPS $(0.62) Misses $(0.53) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581721499","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581721499?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:08","pubTimestamp":1762344491,"startTime":"0","endTime":"0","summary":"Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.53) by 16.32 percent. This is a 16.22 percent increase over losses of $(0.74) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48649313/boundless-bio-q3-eps-0-62-misses-0-53-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BOLD"],"gpt_icon":0},{"id":"2581072172","title":"Boundless Bio Inc: Qtrly EPS $-0.62","url":"https://stock-news.laohu8.com/highlight/detail?id=2581072172","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581072172?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:00","pubTimestamp":1762344007,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nTUA1RX9ZG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BOLD","BK4139"],"gpt_icon":0},{"id":"2581722229","title":"Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2581722229","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581722229?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:00","pubTimestamp":1762344000,"startTime":"0","endTime":"0","summary":"Enrollment ongoing in BBI-355 / BBI-825 combination arm of the POTENTIATE trial  Investigational new drug submission for BBI-940 on track, with a first-in-human clinical trial expected to initiate in ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/05/3181282/0/en/Boundless-Bio-Reports-Third-Quarter-2025-Financial-Results-and-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0187121727.USD","RNR","LU0077335932.USD","LU0347712357.USD","BK4139","BOLD","BK4019","LU2244417387.USD","LU2413666426.HKD","LU1721428933.USD","LU2413666699.HKD"],"gpt_icon":0},{"id":"2575280607","title":"Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2575280607","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575280607?lang=en_us&edition=fundamental","pubTime":"2025-10-14 04:05","pubTimestamp":1760385900,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Oct.  13, 2025  (GLOBE NEWSWIRE) -- Boundless Bio, (Nasdaq: BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/13/3165792/0/en/Boundless-Bio-Announces-Upcoming-Presentation-at-the-2025-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0077335932.USD","BK1584","BK1550","LU2244417387.USD","LU0347712357.USD","BK4139","LU0264606111.USD","LU2413666699.HKD","LU0572939691.SGD","BK4007","BK4202","LU1721428933.USD","BK1184","RNR","LENZ","LU2413666426.HKD","NCI","LU0187121727.USD","01336","BK4539","BOLD","BK4019","LU0572940350.SGD"],"gpt_icon":0},{"id":"2569688317","title":"ESQUIRE VIETNAM RELAUNCHES WITH A BOLD VISION, CELEBRATING THE AGE OF EXCELLENCE","url":"https://stock-news.laohu8.com/highlight/detail?id=2569688317","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569688317?lang=en_us&edition=fundamental","pubTime":"2025-09-23 10:56","pubTimestamp":1758596160,"startTime":"0","endTime":"0","summary":"HO CHI MINH CITY, Vietnam, Sept. 23, 2025 /PRNewswire/ -- Esquire Vietnam officially marks its bold return with a refreshed vision and renewed identity. The relaunch celebrates modern masculinity and honors trailblazers shaping Vietnam's cultural and creative landscape.Pictured at the event: Venus Tran , Founder & CEO of Sun Flower Media, and Dan Q. Dao , Editor-in-Chief.The unveiling of Esquire Vietnam’s return cover, featuring actor Lien Binh Phat.","market":"nz","thumbnail":"https://mma.prnewswire.com/media/2778422/image_5053589_32675033.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2778422/image_5053589_32675033.jpg?w=300"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/esquire-vietnam-relaunches-with-a-bold-vision-celebrating-the-age-of-excellence-302563757.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BOLD"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}]}}